The Need

- Cisgender women are **2-3 times more likely to acquire HIV during pregnancy and 4 times more likely** post-partum than otherwise.

- Women who acquire HIV during pregnancy have an **18% chance of transmitting HIV to their newborn, and up to a 27% chance** if they acquire HIV while breastfeeding.

- The exclusion of Pregnant and Lactating People (PLP) from research results in:
  - A lack of data on dosing and maternal and fetal safety.
  - Limitations around prescribing potentially beneficial interventions.
  - Exclusion from potential direct benefits of research participation.
  - Delays and discrepancies in health policies and programs.

- HIV prevention options for PLP are limited, and there are **major evidence gaps** across studies of oral and injectable pre-exposure prophylaxis (PrEP), vaginal rings and gels, monoclonal antibodies and vaccines.

PLP include cisgender women, transgender men and those who identify as gender non-binary who are able to get pregnant. For transgender and gender-diverse pregnant people, evidence is glaringly absent—a reflection of the overall failure to conduct meaningful HIV prevention research in gender-diverse populations. Research is needed to better understand the potential population size of those likely to become pregnant, barriers to accessing HIV prevention, interactions between hormones and HIV prevention options and their implications on safety and efficacy.

Aside from recent exceptions, most biomedical HIV research excludes PLP, and those who become pregnant during a trial are stopped from further use of the study drug (see Figure 4 for details pointing to progress). Researchers, ministries of health, funders and governments often make protectionist decisions around PLP in trials that are ultimately disempowering and reinforce their heightened HIV risk (Figure 1).

**Figure 1: Current Practices Resulting in Delayed Data in PLP (WHO/IMPAACT, 2021)**

Historical approach aims primarily to protect the fetus/infant from harm.

Many disincentives for industry, funders & researchers to include PLP in trials.

Full nonclinical developmental and reproductive toxicology (DART) data often not available until late in drug development.

Most current pregnancy/lactation data arise from post-marketing opportunistic studies of women receiving antiretrovirals for clinical care.

Minimal systematic post-marketing surveillance or observational studies that evaluate pregnancy and other outcomes following drug licensure and widespread use.

Lessons from Ebola and COVID-19

During the 2013-2016 Ebola outbreak, pregnant women were at high risk—previous outbreaks showed up to 93% maternal and 100% fetal/neonatal mortality. Clinical trials were the only source of access to potentially life-saving interventions, but pregnant women were excluded from all drug and vaccine trials out of a desire to contain research risk. This exclusion left pregnant women and their children “protected to death”.

In the case of the COVID-19 pandemic, pregnant individuals who contracted COVID-19 had higher rates of adverse outcomes, including maternal mortality, preeclampsia and preterm birth. Despite increased risk,
PLP remained excluded from most vaccine trials until February 2021—months after vaccines received emergency use authorization and were publicly rolled out. Without definitive guidance, pregnant people and their clinicians were left to weigh the risks of COVID-19 with the unknown safety risks of the vaccines when determining whether to get vaccinated.

**Reframing through a Reproductive Justice Lens**

There is a need to reframe the importance of the inclusion of PLP in clinical trials as a reproductive justice issue. **Reproductive justice** is the human right to maintain personal bodily autonomy, have children, not have children and parent children in safe and healthy communities. Developed by a Black women’s collective in 1994, reproductive justice elevates and centers the needs, voices, lived experiences and leadership of African and other Black and Brown women, transgender and gender-diverse people and youth. Under this framework, pregnant individuals have the human right to maintain personal bodily autonomy, which includes responsible, ethical involvement in clinical trials and access to life-saving prevention.

**Progress**

Since 2017, a number of initiatives have been established to address the exclusion of PLP in research. One such initiative, the Pregnancy and HIV/AIDS Seeking Equitable Study (PHASES), identified three critical paradigm shifts needed to move towards an ethical framework for the inclusion of this population (Figure 2). The shifts are: considering pregnant women as a complex population rather than a vulnerable population; protecting pregnant women through research rather than from research; and promoting fair inclusion in clinical drug trials, rather than presumptive exclusion from them. This re-framing facilitates responsible inclusion of PLP in research as the default rather than the exception.

**Figure 2: Ethical Shifts in the Framing of Research in PLP (Phases, 2020)**

Most recently, the World Health Organization (WHO), the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) and the International AIDS Society (IAS) released a Call to Action that includes a new framework for accelerating inclusion in clinical trials. A primary goal of the framework is to have pharmacokinetic (PK) and preliminary safety data on all new HIV agents in pregnancy available at the time of drug approval. The call to action also outlines the roles of various stakeholders in supporting greater inclusion.

Informed by such consensus recommendations, AVAC and PHASES held a multi-disciplinary think tank and civil society convening in 2022 to identify priority actions and develop an action plan for moving them forward. The action plan outlines four priority goals for advancing responsible research in PLP, with specific objectives and action steps for each. The goals speak to framing the need for inclusion through a rights-based reproductive justice lens; early, sustained and meaningful stakeholder engagement; harmonized regulatory frameworks; and supportive ethics review processes. Figure 3 contains details on these and other key initiatives, namely Pregnancy Research Ethics for Vaccines, Epidemics, and New Technologies (PREVENT) and the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC). Together, these initiatives call for and document a global consensus for more inclusion of these populations in HIV research.
## Figure 3: Select PLP Initiatives

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Purpose</th>
<th>Key Goals/Priorities</th>
</tr>
</thead>
</table>
| **Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC)** | Provide ethics guidance at the intersection of pregnancy, vaccines and emerging and re-emerging epidemic threats (Global) | - Pregnant women are not unjustifiably excluded from participating in vaccine studies  
- Pregnant women and their offspring benefit from advances in vaccine technologies  
- Pregnant women have access to safe and effective vaccines to protect them and their offspring |
| 2018: PRGLAC Report, Recommendations and Implementation Plan | Advise the US Secretary of Health and Human Services (HHS) regarding gaps in knowledge and research on safe and effective therapies for pregnant and lactating women (US) | Alter “protective” cultural assumptions that have significantly limited scientific knowledge of therapeutic product safety, effectiveness and dosing for pregnant and lactating women |
| **2020: Ending the Evidence Gap for Pregnant Women Around HIV & Co-Infections: A Call to Action** | Provide concrete and immediately actionable recommendations for advancing timely, needed, responsible research with pregnant women on new and existing preventives and treatments for HIV and its co-infections (Global) | - Equitable protection of pregnant and breastfeeding women  
- Increased access to first line therapeutics for pregnant and breastfeeding women  
- Respect the health of the woman |
| **2021: Research for Informed Choices: Accelerating the Study of New Drugs for HIV in Pregnant and Breastfeeding Women: A Call to Action** | Gain consensus on the optimal timing and design of studies of new agents for treating and preventing HIV and related conditions in pregnant women, identify strategies to accelerate the study of new agents during pregnancy and formulate a strategic action plan for promoting the inclusion of pregnant women in research of new HIV agents (Global) | - Early and sustained community engagement  
- Completion of Developmental and Reproductive Toxicity (DART) studies earlier during drug development  
- Offer option to women who become pregnant in pre-licensure trials to stay on study drug (if no indicators of negative safety signals)  
- Conduct pregnancy pharmacokinetic (PK) and preliminary safety earlier  
- Investigate adverse pregnancy and birth outcomes through dedicated pregnancy safety studies  
- Expand active surveillance of drug safety in pregnancy |
| **Think Tank to Advance HIV Prevention Research in PLP** | Identify priority objectives, informed by consensus recommendations, and develop an action plan to accelerate HIV prevention research with PLP (Global) | Advance responsible HIV prevention research in PLP by:  
- Using a reproductive justice framework  
- Early, sustained and meaningful stakeholder engagement  
- Harmonized regulatory frameworks  
- Supportive ethics review processes |
| 2022: Think Tank Action Plan for Advancing HIV Prevention Research in PLP | | |
**PLP in Ongoing HIV Prevention Trials**

Despite increasing support in recent years, PLP are often left out of HIV prevention research or considered as an “afterthought” when designing studies. Figure 4 outlines the current plans for inclusion of PLP in ongoing large-scale HIV prevention trials.

**Figure 4: HIV Prevention Research Pipeline for PLP**

<table>
<thead>
<tr>
<th>Efficacy Trial</th>
<th>Inclusion Criteria</th>
<th>Ongoing Research</th>
<th>Prevention Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaginal Ring</td>
<td>DELIVER and B-PROTECTED: safety, drug levels and adherence (but not efficacy) in pregnant and breastfeeding women</td>
<td>No known safety risks early in pregnancy. Low drug levels in breastmilk</td>
<td></td>
</tr>
<tr>
<td>Dapivirine Ring (Monthly)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral PrEP</td>
<td>Women who become pregnant can reconsent to sub-study in PLW and their infants</td>
<td>No evidence</td>
<td></td>
</tr>
<tr>
<td>F/TAF (Daily pill)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Islatravir (Monthly pill)</td>
<td>Women who become pregnant can reconsent to continue study drug, but no data is expected</td>
<td>No evidence</td>
<td></td>
</tr>
<tr>
<td>Long-Acting Injectable</td>
<td>HPTN 084 OLE: pregnancy incidence, safety and infant outcomes, CAB concentration in pregnant women</td>
<td>No pregnancy-related adverse events, neural tube defects, birth defects in 29 women who became pregnant in HPTN 084</td>
<td></td>
</tr>
<tr>
<td>Cabotegravir (Every two months)</td>
<td>Women who become pregnant can reconsent to sub-study in PLW and their infants</td>
<td>No evidence</td>
<td></td>
</tr>
<tr>
<td>Lenacapavir (Every six months)</td>
<td>TG men and GNC people who become pregnant can reconsent to sub-study in PLP and their infants</td>
<td>No evidence</td>
<td></td>
</tr>
<tr>
<td>Preventive HIV Vaccine</td>
<td>No ongoing vaccine or antibody efficacy trials</td>
<td>Meta-analysis of Phase 1 &amp; 2a vaccine studies showed no signal of increased risk for pregnancy or birth (based on 193 pregnancies)</td>
<td></td>
</tr>
</tbody>
</table>

PLP included at enrollment

PLP excluded at enrollment
What can advocates do?

Advocates have a critical role to play in advancing HIV prevention research in PLP. From consultation with a wide range of HIV and women’s health advocates in the AVAC/PHASES Think Tank and the WHO/IMPAACT/IAS Call to Action, several key actions emerged. These include:

**Asking key questions throughout all stages of research and surveillance**

- For clinical and implementation research protocols and ongoing clinical studies:
  - Have Developmental and Reproductive Toxicity (DART) studies been completed with no negative signals? Has dosing in non-pregnant women been established? If not, what is the plan to ensure these studies are completed and by when? If yes to both, are contraception requirements in place for trial participants? Why?
  - If contraceptive requirements are indicated, do they incorporate evidence-based contraceptive counseling and do women have access to other sexual and reproductive health services through the site? If not, why?
  - If contraceptive requirements are not indicated, are trial sites still offering access to evidence-based contraceptive counseling and other sexual and reproductive health services? If not, why?
  - Are cisgender women and gender-diverse pregnant people included in the study? If not, why?
  - Are lactating people included in the study? If not, why?
  - Will study data be disaggregated for different populations?
  - What is the plan for those who become pregnant during the study? Will specific data on key outcomes be collected in these individuals?
  - What is the stakeholder engagement plan? Does the plan detail early and sustained engagement that aligns with the Good Participatory Practice (GPP) Guidelines?
  - Do these plans include engagement of participants’ communities and especially influencers (i.e., families, partners, community leaders)?

- For implementation research and rollout:
  - Are PLP included or excluded in the eligibility criteria? If excluded, why?
  - What data are still needed on access, feasibility and acceptability for PLP for the specific interventions? How is this data being collected?
  - Do implementation studies link to an existing pregnancy registry to follow long-term outcomes?
  - For approved products with inadequate data in PLP, what is the plan for gathering data?

**Taking the lead in building community literacy, peer education and advocacy**

- Identify, develop and disseminate resources and tools to build other advocates’ knowledge about the need for inclusion of PLP in HIV prevention research
Help normalize research in PLP by engaging a broad range of community stakeholders, especially PLP and people of reproductive potential, their partners and family members, community leaders and physicians

Engage pregnant people, adolescents and transgender and gender-diverse individuals and their communities to co-develop advocacy messages that give voice to their lived experiences and ensure research agendas are reflective of their needs

Seek out other advocates and stakeholders addressing maternal health and reproductive justice issues to identify opportunities for collaboration and amplify efforts to address intersecting issues including racial and gender-based disparities as well as other diseases (e.g., malaria, cancer, TB) that differentially impact these populations

**Advocating for and supporting regulatory and ethics processes that protect PLP through research**

Identify and coordinate with key stakeholders to encourage national governments to bolster the ability of drug regulatory agencies to incentivize and/or require the generation of data specific to PLP for approval of new therapeutics

Encourage the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), African Medicines Regulatory Harmonisation (AMRH) and other drug regulatory harmonization organizations to develop guidelines for the responsible inclusion of PLP in pre-licensure drug development trials

Support ongoing efforts by WHO to advance harmonization of regulatory frameworks, promoting inclusive involvement of national and regional regulatory bodies in areas with high HIV burden. Harmonization would accelerate PLP-specific data as early as possible in product development and facilitate timely public availability of data

Develop and disseminate tools and resources to support investigators and research ethics committees/institutional review boards to consider responsible inclusion of PLP in the ethics review process

---

**About AVAC**

AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of new HIV prevention options as part of a comprehensive response to the pandemic. For more information, visit [www.avac.org](http://www.avac.org).